{'fraction_non_alphanumeric': 0.06275805119735756, 'fraction_numerical': 0.08587943848059455, 'mean_word_length': 4.434977578475336, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clival chordoma metastatic to right lateral ventricle: A case report

Suppl 2 – S15 information of age, gender, location of the tumor and treatment. Results: From 200 citations, 136 patients from 90 articles were identified with T-cell PCNSL and majority of them were case reports or case series. There were 16 cases reported between years 1980-1990, 54 from 1990-2000, and 66 from 2000-2013. Men outnumber women by 2:1. The median age of the patients was 42.5 (range 2 to 79) years and the median overall survival (OS) was 14.0 (95%CI 13.3 to 20.1) months for those with age d64 years compared to 8.0 (95%CI 4.8 to 14.1) months for those with age >64 years (P=0.0033). Fifty-one patients received methotrexate-based chemotherapy and only 46% achieved a complete response (CR). There was no difference between the Kaplan-Mier overall survival of patients diagnosed with solitary versus multiple tumors (χ 2 =0.3, P=0.6090), treated versus nottreated with methotrexate (χ 2 =0.1, P=0.7420), and achieved CR versus non-CR status after methotrexate therapy (χ 2 =0.4, P=0.5470). Conclusion: T-cell PCNSL appears to be more aggressive and less responsive to methotrexate-based treatment than the majority of PCNSLs.